View in EDS

Olorofim for the treatment of invasive fungal diseases in patients with few or no therapeutic options: a single-arm, open-label, phase 2b study.

Saved in:
Bibliographic Details
Title: Olorofim for the treatment of invasive fungal diseases in patients with few or no therapeutic options: a single-arm, open-label, phase 2b study.
Authors: Maertens, Johan A1,2 (AUTHOR) johan.maertens@uzleuven.be, Thompson III, George R3 (AUTHOR), Spec, Andrej4 (AUTHOR), Donovan, Fariba M5 (AUTHOR), Hammond, Sarah P6,7 (AUTHOR), Bruns, Anke H W8 (AUTHOR), Rahav, Galia9 (AUTHOR), Shoham, Shmuel10 (AUTHOR), Johnson, Royce11,12 (AUTHOR), Rijnders, Bart13 (AUTHOR), Schaenman, Joanna11,14 (AUTHOR), Hoenigl, Martin15,16 (AUTHOR), Morrissey, C Orla17,18 (AUTHOR), Mehta, Sanjay R19,20 (AUTHOR), Heath, Christopher H21,22,23 (AUTHOR), Koehler, Philipp24,25,26 (AUTHOR), Paterson, David L27,28 (AUTHOR), Slavin, Monica A29,30 (AUTHOR), Fortún, Jesus31,32,33,34 (AUTHOR), Nguyen, M Hong35 (AUTHOR)
Source: Lancet Infectious Diseases. Nov2025, Vol. 25 Issue 11, p1177-1188. 12p.
Database: Academic Search Ultimate
Description
ISSN:14733099
DOI:10.1016/S1473-3099(25)00224-5